A Study to Evaluate the Effects of a Prebiotic and Probiotic Supplement to Provide Relief From Symptoms Associated With Bacterial Vaginosis and Yeast Infections.

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age25+
SponsorHappy V

About this trial

This virtual randomized controlled trial evaluates the efficacy of a prebiotic and probiotic supplement in providing relief from symptoms associated with bacterial vaginosis and yeast infections. Participants will be randomized into three groups-test product, active placebo, and excipient placebo-and will take two capsules daily for 30 days. The study will assess the effects on vaginal microbiome, symptoms of bacterial vaginosis and yeast infections, and overall vaginal health.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women

Age 25+

Self-reported concerns symptoms associated with bacterial vaginosis or candida overgrowth, including itchiness, redness, abnormal discharge, and an unpleasant odor.

Suffers from digestive issues, including bloating, gas, or other digestive discomfort.

Disqualifiers

Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders

Planning to undergo any procedure related to their vaginal health.

Started any new medications or supplements that target vaginal health in the past 3 months.

Anyone with known severe allergic reactions that require the use of an Epi-Pen, or any known allergies to any of the product ingredients

Trial design

Design model

Parallel

Treatments tested in this trial

  • Prebiotic + Probiotic Supplement

    Dietary supplement

    This intervention includes a combination of prebiotics and probiotics designed to promote vaginal and digestive health. The supplement contains Biotin, Lactobacillus acidophilus (as LA-14®), Bifidobacterium lactis (HN019™), Lactobacillus rhamnosus (as HN001™), Lactobacillus crispatus (as CCFM1110™), Lactobacillus gasseri (as HLG13™), Lactobacillus reuteri (as HR7™), Bacillus subtilis (as DE111®), PreforPro®, White Rice Flour, Magnesium Stearate (Vegetable Source), Silicon Dioxide (Bamboo Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.

  • Active Placebo Supplement

    Dietary supplement

    The active placebo supplement contains similar probiotic strains without the prebiotic component. Ingredients include Biotin, Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus rhamnosus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus reuteri, Bacillus subtilis, Inulin (from Chicory Root), White Rice Flour, Magnesium Stearate (Vegetable Source), Silicon Dioxide (Bamboo Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.

  • Excipient Placebo Supplement

    Dietary supplement

    The excipient placebo supplement contains no active ingredients related to prebiotics or probiotics. It includes White Rice Flour, Magnesium Stearate (Vegetable Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.

Treatment groups

120 Participants
are divided into 3 treatment groups
Group A: Test Product GroupExperimental treatment 1 intervention
Group B: Active Placebo GroupPlacebo comparator 1 intervention
Group C: Excipient Placebo GroupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in Vaginal Microbiome

This outcome measures the change in vaginal microbiome parameters from Baseline to Day 30. The vaginal microbiome will be assessed using microbiome sequencing at both Baseline and Day 30.

Time frame
Baseline, Day 30

Secondary outcomes

1

Change in Perceived Symptoms of Bacterial Vaginosis

This outcome measures the change in symptoms associated with bacterial vaginosis and yeast infections (e.g., itchiness, odor, abnormal discharge) as reported by participants through questionnaires.

Time frame
Baseline, Day 1, Day 7, Day 14, Day 21, Day 30
2

Change in Perceived Symptoms of Yeast Infections

This outcome measures the change in symptoms associated with bacterial vaginosis and yeast infections (e.g., itchiness, odor, abnormal discharge) as reported by participants through questionnaires.

Time frame
Baseline, Day 1, Day 7, Day 14, Day 21, Day 30

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Happy V

Lead sponsor

Citruslabs

Collaborator

This trial is not recruiting at the moment. You can still explore other options: